MissionIR News - Seeking Alpha Publishes Article Featuring Galena Biopharma

Article features Galena Biopharma’s top investment highlights, considerations and financial projections

MissionIR would like to highlight Galena Biopharma, Inc., a biopharmaceutical company focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company’s peptide vaccine immunotherapies utilize the patient’s own immune system to identify and destroy cancer cells. Enhanced by multiple development and commercial collaborations, the company’s suite of immunotherapeutic solutions is poised to capitalize on the vast opportunities in today’s healthcare industry.

Seeking Alpha has published the following article featuring Galena: http://seekingalpha.com/article/1610482-galena-biopharma-presents-an-attractive-investment-opportunity

The article titled “Galena Biopharma Presents an Attractive Investment Opportunity” offers a brief overview of Galena management and takes into consideration the company’s science, technical status, fundamentals and future catalysts for upcoming growth.

Looking at the stock’s one-year chart shows a gain of more than 37 percent in the last 52 weeks, reversing a recent downturn. The stock’s performance outpaced the healthcare and broader market-related ETFs. To compare, the Healthcare ETF has increased by roughly 33 percent over the last year while S&P 500 ETF has risen 22 percent for the same period.

Galena’s attractive drug pipeline demonstrates its opportunities for growth and generating revenues. In addition to its upcoming launch of the company’s FDA-approved cancer pain treatment, Abstral, Galena is continuing to develop NeuVax for the treatment of breast cancer. 

In late 2012, Galena signed an agreement with Teva Pharmaceuticals (TEVA) to commercialize NeuVax in the country of Israel, freeing Galena to focus on the actual trials and save available cash since the agreement calls for Teva to fund commercialization. As part of the deal, shareholders can expect to see a large royalty on any NeuVax sales that occur in Israel.

The article also points to Galena’s financial standing. As of May 13, 2013, Galena had approximately $30.2 million available cash and approximately $10 million of long-term debt. With a burn rate of $1.25 million per month, cash on hand will likely run low in the second half of 2014, though Galena expects to earn up to $3 million this year and between $8 million - $12 million in 2014 upon success of the launch of Abstral.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.